Research and Development: Comparing Key Metrics for Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc.

R&D Spending: Takeda vs. TG Therapeutics Over a Decade

__timestampTG Therapeutics, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 201431354781382096000000
Thursday, January 1, 201543445817345927000000
Friday, January 1, 201666489820312303000000
Sunday, January 1, 201796886134325441000000
Monday, January 1, 2018153793000368298000000
Tuesday, January 1, 2019148369000492381000000
Wednesday, January 1, 2020151934000455833000000
Friday, January 1, 2021198532000526087000000
Saturday, January 1, 2022112128000633325000000
Sunday, January 1, 202376192000729924000000
Monday, January 1, 2024729924000000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. Takeda, a global leader, has consistently allocated substantial resources, with R&D expenses peaking at approximately 730 billion yen in 2023, marking a 91% increase since 2014. In contrast, TG Therapeutics, a smaller biotech firm, has shown a more volatile pattern, with R&D spending reaching its zenith in 2021, before declining by 62% in 2023. This divergence highlights the strategic differences between established giants and emerging innovators. While Takeda's steady investment underscores its commitment to long-term growth, TG Therapeutics' fluctuating expenses reflect the dynamic nature of biotech ventures. As we look to the future, these trends offer valuable insights into the evolving landscape of pharmaceutical innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025